DEA Reviews Bid to Import LSD by Pharma Services Giant
Published Date: 1/8/2026
Notice
Summary
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some tightly regulated drugs like LSD. People and companies involved can share their thoughts or ask for a hearing by February 9, 2026. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
No commercial finished-dosage imports allowed
The notice says approval will not authorize importing Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale under this registration. No other activity for the listed drug code is authorized for this registration.
LSD import application for clinical trials
On December 5, 2025, AndersonBrecon, Inc. DBA PCI Pharma Services applied to be registered to import lysergic acid diethylamide (LSD), controlled substance code 7315, Schedule I. The company says it plans to import this drug for clinical trials only.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in